These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16718882)

  • 1. Report from the 13th retrovirus conference. Extending the role of atazanavir.
    Feinberg J
    AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
    [No Abstract]   [Full Text] [Related]  

  • 2. Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):98. PubMed ID: 19271333
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
    TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
    [No Abstract]   [Full Text] [Related]  

  • 4. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):80. PubMed ID: 20458811
    [No Abstract]   [Full Text] [Related]  

  • 5. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-HIV agents. Atazanavir vs. Kaletra.
    TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
    [No Abstract]   [Full Text] [Related]  

  • 8. PI monotherapy effective as maintenance.
    AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug profile: atazanavir (Reyataz, ATV).
    Pham PA
    Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
    [No Abstract]   [Full Text] [Related]  

  • 10. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
    TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
    [No Abstract]   [Full Text] [Related]  

  • 12. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
    Sax PE
    AIDS Clin Care; 2003 Sep; 15(9):78. PubMed ID: 14666914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 14. Boosted Reyataz: 48-week results.
    Huff B
    GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
    [No Abstract]   [Full Text] [Related]  

  • 15. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-HIV agents. Kaletra + atazanavir.
    TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
    Petersen K; Riddle MS; Jones LE; Furtek KJ; Christensen AR; Tasker SA; Hale BR
    AIDS; 2005 Oct; 19(15):1700-2. PubMed ID: 16184044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unusual case of HIV virologic failure during treatment with boosted atazanavir.
    Duncan A; Mills J
    AIDS; 2013 May; 27(8):1361-2. PubMed ID: 23925384
    [No Abstract]   [Full Text] [Related]  

  • 19. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
    Rubio R; Serrano O; Carmena J; Asensi V; Echevarría S; Flores J; Ribera E; Zarraga M; Ocampo A; de la Fuente B; Sepúlveda MA; Mariño AI; Minguez C; Vicent R; Cartón JA; Moyano B; Esteban H; Mahillo B; Serrano L; González-García J;
    HIV Med; 2010 Oct; 11(9):545-53. PubMed ID: 20345884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.